Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Ellen Chiniara Sells 2,241 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Ellen Chiniara sold 2,241 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $68,238.45. Following the sale, the insider now owns 80,085 shares in the company, valued at approximately $2,438,588.25. This trade represents a 2.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Ellen Chiniara also recently made the following trade(s):

• On Monday, January 6th, Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock. The shares were sold at an average price of $41.75, for a total value of $130,635.75.

Kymera Therapeutics Stock Down 3.8 %

KYMR opened at $30.17 on Tuesday. The stock’s fifty day moving average is $38.81 and its two-hundred day moving average is $43.66. The company has a market capitalization of $1.95 billion, a P/E ratio of -12.89 and a beta of 2.18. Kymera Therapeutics, Inc. has a 52 week low of $29.16 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The firm had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Leerink Partners restated an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. BMO Capital Markets assumed coverage on Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 price objective on the stock. Morgan Stanley upped their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 6th. HC Wainwright upped their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research report on Friday. Finally, UBS Group reduced their price target on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $56.69.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of KYMR. Wellington Management Group LLP increased its holdings in Kymera Therapeutics by 14.9% during the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock worth $213,514,000 after purchasing an additional 688,967 shares during the period. Avoro Capital Advisors LLC boosted its position in Kymera Therapeutics by 14.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after acquiring an additional 650,000 shares in the last quarter. Deerfield Management Company L.P. Series C bought a new stake in Kymera Therapeutics during the 4th quarter valued at $23,856,000. Boxer Capital Management LLC bought a new stake in Kymera Therapeutics during the 4th quarter valued at $17,098,000. Finally, Jennison Associates LLC boosted its position in Kymera Therapeutics by 85.8% during the 3rd quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock valued at $37,754,000 after acquiring an additional 368,394 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.